Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.80 |
| ▸ | PGR | P06401 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | TNF | P01375 | 1/20 | 0.80 |
| ▸ | IL6 | P05231 | 1/20 | 0.80 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.80 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.80 |
| ▸ | AR | P10275 | 1/20 | 0.80 |
| ▸ | GLUL | P15104 | 1/20 | 0.80 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.80 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loteprednol SCHEMBL13379818 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL8859679 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL12396678 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL1685771 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL23974936 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL1626518 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL23974878 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL12738241 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL15803210 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 | |
| Loteprednol SCHEMBL32678555 | 1.00 | NR3C1 (0.80) | NR3C1HIF1APGRHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | claimed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | claimed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, ADRB2, ADRB1 | NR3C1 16/4885HIF1A 3363/4885PGR 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.